S
Stefanie Schulz
Researcher at Technische Universität München
Publications - 105
Citations - 6610
Stefanie Schulz is an academic researcher from Technische Universität München. The author has contributed to research in topics: Percutaneous coronary intervention & Clopidogrel. The author has an hindex of 41, co-authored 105 publications receiving 6186 citations.
Papers
More filters
Journal ArticleDOI
Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention
Adnan Kastrati,Franz-Josef Neumann,Julinda Mehilli,Robert A. Byrne,Raisuke Iijima,Heinz Joachim Büttner,Ahmed A. Khattab,Stefanie Schulz,James C. Blankenship,Jürgen Pache,Jan Minners,Melchior Seyfarth,Isolde Graf,Kimberly A. Skelding,Josef Dirschinger,Gert Richardt,Peter B. Berger,Albert Schömig +17 more
TL;DR: In patients with stable and unstable angina who underwent PCI after pretreatment with clopidogrel, bivalirudin did not provide a net clinical benefit as compared with unfractionated heparin, but it did significantly reduce the incidence of major bleeding.
Journal ArticleDOI
Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial.
Robert A. Byrne,Franz-Josef Neumann,Julinda Mehilli,Susanne Pinieck,Britta Wolff,Klaus Tiroch,Stefanie Schulz,Massimiliano Fusaro,Ilka Ott,Tareq Ibrahim,Jörg Hausleiter,Christian M. Valina,Jürgen Pache,Karl-Ludwig Laugwitz,Steffen Massberg,Adnan Kastrati +15 more
TL;DR: By obviating the need for additional stent implantation, PEB could be a useful treatment for patients with restenosis after implantation of a drug-eluting stent.
Journal ArticleDOI
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Julinda Mehilli,Adnan Kastrati,Stefanie Schulz,Stefan Früngel,Stephan G. Nekolla,Werner Moshage,Franz Dotzer,Kurt Huber,Jürgen Pache,Josef Dirschinger,Melchior Seyfarth,Stefan Martinoff,Markus Schwaiger,Albert Schömig +13 more
TL;DR: Upstream administration of abciximab is not associated with a reduction in infarct size in patients presenting with acute myocardial infarction within 24 hours of symptom onset and receiving 600 mg clopidogrel.
Journal ArticleDOI
Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
Tomohisa Tada,Robert A. Byrne,Iva Simunovic,Lamin A. King,Salvatore Cassese,Michael Joner,Massimiliano Fusaro,Simon Schneider,Stefanie Schulz,Tareq Ibrahim,Ilka Ott,Steffen Massberg,Karl-Ludwig Laugwitz,Adnan Kastrati +13 more
TL;DR: In a large cohort of unselected patients undergoing coronary stenting, compared with BMS, there was a significant excess risk of stent thrombosis at 3 years with G1-DES, driven by an increased risk ofStent thromabosis events beyond 1 year.
Journal ArticleDOI
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
Adnan Kastrati,Franz-Josef Neumann,Stefanie Schulz,Steffen Massberg,Robert A. Byrne,Miroslaw Ferenc,Karl-Ludwig Laugwitz,Jürgen Pache,Ilka Ott,Jörg Hausleiter,Melchior Seyfarth,Michael Gick,David Antoniucci,Albert Schömig,Peter B. Berger,Julinda Mehilli,Isar-React Trial Investigators +16 more
TL;DR: Abciximab and unfractionated heparin, as compared with bivalirudin, failed to reduce the rate of the primary end point and increased the risk of bleeding among patients with non-ST-segment elevation myocardial infarction who were undergoing PCI.